
TY  - JOUR
AU  - O’Donoghue, S. D.
AU  - Dulhunty, J. M.
AU  - Bandeshe, H. K.
AU  - Senthuran, S.
AU  - Gowardman, J. R.
TI  - Acquired hypernatraemia is an independent predictor of mortality in critically ill patients
JO  - Anaesthesia
VL  - 64
IS  - 5
SN  - 0003-2409
UR  - https://doi.org/10.1111/j.1365-2044.2008.05857.x
DO  - doi:10.1111/j.1365-2044.2008.05857.x
SP  - 514
EP  - 520
PY  - 2009
AB  - Summary This study reports the incidence and associated mortality of acquired hypernatraemia (Na?> 150?mmol.l?1) in a general medical/surgical intensive care unit. Patients admitted over a 5-year period with normal sodium values were eligible for inclusion; exclusions were made for burn/neurosurgical diagnoses and for hypertonic saline therapy. From 3475 admissions (3317 patients), 266 (7.7%) episodes of hypernatraemia were observed. Hospital mortality was 33.5% in the hypernatraemic group and 7.7% in the normonatraemic group (p?<?0.001). Acquired hypernatraemia was an independent risk factor for in-hospital mortality (OR 1.97, 95% CI 1.37?2.82, p?<?0.001). Intermediate sodium levels (145?150?mmol.l?1) were associated with increased mortality (OR 1.42, 95% CI 1.02?1.98). Uncorrected sodium at discharge (p?=?0.001) and peak sodium (p?=?0.001) were better predictors of mortality than time to onset (p?=?0.71) and duration of hypernatraemia (p?=?1.0). Hypernatraemia avoidance is justified, but determinants of hypernatraemia and benefits of targeted treatment strategies require further elucidation.
ER  - 

TY  - JOUR
TI  - Scientific Programme 44th Annual Meeting of the International Continence Society (ICS) 20—24 October 2014, Rio de Janeiro, Brazil
JO  - Neurourology and Urodynamics
JA  - Neurourol. Urodynam.
VL  - 33
IS  - 6
SN  - 0733-2467
UR  - https://doi.org/10.1002/nau.22655
DO  - doi:10.1002/nau.22655
SP  - 631
EP  - 1071
PY  - 2014
ER  - 

TY  - JOUR
TI  - ASBMR 29th Annual Meeting
JO  - Journal of Bone and Mineral Research
JA  - J Bone Miner Res
VL  - 22
IS  - S1
SN  - 0884-0431
UR  - https://doi.org/10.1002/jbmr.5650221408
DO  - doi:10.1002/jbmr.5650221408
SP  - s302
EP  - s351
PY  - 2007
ER  - 

TY  - JOUR
AU  - HARRIS, DAVID
TI  - Acute renal replacement – which treatment is best?
JO  - Australian and New Zealand Journal of Medicine
VL  - 20
IS  - 3
SN  - 0004-8291
UR  - https://doi.org/10.1111/j.1445-5994.1990.tb01017.x
DO  - doi:10.1111/j.1445-5994.1990.tb01017.x
SP  - 197
EP  - 200
PY  - 1990
ER  - 

TY  - JOUR
AU  - Palladino, Michael
AU  - Thomson, Lynda
AU  - Swift,, Brian
AU  - Merli, Geno J.
TI  - Implementing the new oral anticoagulants into the hospital formulary
JO  - American Journal of Hematology
JA  - Am. J. Hematol.
VL  - 87
IS  - S1
SN  - 0361-8609
UR  - https://doi.org/10.1002/ajh.23208
DO  - doi:10.1002/ajh.23208
SP  - S127
EP  - S132
PY  - 2012
AB  - Abstract The new oral anticoagulants may prove to be one of most significant innovations in clinical practice in the past 60 years. Apixaban and rivaroxaban are direct inhibitors of Factor Xa, while dabigatran inhibits Factor IIa. The predictable pharmacological profile of these new agents allows physicians to prescribe these drugs without the need for routine coagulation monitoring, which is the mainstay of warfarin therapy. In addition, these new agents have not been shown to have any food interactions and minimal drug?drug interactions, interactions are limited to the p-glycoprotein (p-Gp) transporter or cytochrome P450 (CYP450) system, each drug is unique in its drug interaction profile, as will be discussed below. These unique pharmacokinetics profiles may usher in for clinicians a new era of managing thromboembolic disorders. In this article, the pharmacology of these new oral anticoagulants will be reviewed along with the major clinical trials evaluating the use of these agents for thromboembolic prophylaxis in patients undergoing total hip and knee arthroplastic surgery, the treatment of venous thromboembolic disorders and stroke prevention in atrial fibrillation. Am. J. Hematol., 2012. ? 2012 Wiley Periodicals, Inc.
ER  - 

TY  - JOUR
AU  - Sasaki, Kazunari
AU  - Firl, Daniel J.
AU  - McVey, John C.
AU  - Schold, Jesse D.
AU  - Iuppa, Giuseppe
AU  - Diago Uso, Teresa
AU  - Fujiki, Masato
AU  - Aucejo, Federico N.
AU  - Quintini, Cristiano
AU  - Eghetsad, Bijan
AU  - Miller, Charles M.
AU  - Hashimoto, Koji
TI  - Elevated Risk of Split-Liver grafts in adult liver Transplantation: Statistical Artifact or Nature of the Beast?
JO  - Liver Transplantation
JA  - Liver Transpl
VL  - 25
IS  - 5
SN  - 1527-6465
UR  - https://doi.org/10.1002/lt.25409
DO  - doi:10.1002/lt.25409
SP  - 741
EP  - 751
PY  - 2019
AB  - A recent study using US national registry data reported, using Cox proportional hazards (PH) models, that split-liver transplantation (SLT) has improved over time and is no more hazardous than whole-liver transplantation (WLT). However, the study methods violated the PH assumption, which is the fundamental assumption of Cox modeling. As a result, the reported hazard ratios (HRs) are biased and unreliable. This study aimed to investigate whether the risk of graft survival (GS) in SLT has really improved over time, ensuring attention to the PH assumption. This study included 80,998 adult deceased donor liver transplantation (LT) (1998-2015) from the Scientific Registry Transplant Recipient. The study period was divided into 3 time periods: era 1 (January 1998 to February 2002), era 2 (March 2002 to December 2008), and era 3 (January 2009 to December 2015). The PH assumption was tested using Schoenfeld?s test, and where the HR of SLT violated the assumption, changes in risk for SLT over time from transplant were assessed. SLT was performed in 1098 (1.4%) patients, whereas WLT was used in 79,900 patients. In the Cox PH analysis, the P values of Schoenfeld?s global tests were <0.05 in all eras, which is consistent with deviation from proportionality. Assessing HRs of SLT with a time-varying effect, multiple Cox models were conducted for post-LT intervals. The HR curves plotted according to time from transplant were higher in the early period and then decreased at approximately 1 year and continued to decrease in all eras. For 1-year GS, the HRs of SLT were 1.92 in era 1, 1.52 in era 2, and 1.47 in era 3 (all P < 0.05). In conclusion, the risk of SLT has a time-varying effect and is highest in the early post-LT period. The risk of SLT is underestimated if it is evaluated by overall GS. SLT was still hazardous if the PH assumption was considered, although it became safer over time.
ER  - 

TY  - JOUR
TI  - Scientific Abstracts
JO  - Pediatric Transplantation
VL  - 13
IS  - s1
SN  - 1397-3142
UR  - https://doi.org/10.1111/j.1399-3046.2009.01146.x
DO  - doi:10.1111/j.1399-3046.2009.01146.x
SP  - 46
EP  - 156
PY  - 2009
ER  - 

TY  - JOUR
AU  - Soltani, Akbar
AU  - Hasani-Ranjbar, Shirin
AU  - Moayyeri, Alireza
TI  - Hypocalcemia as a presentation for multifocal osteosarcoma
JO  - Pediatric Blood & Cancer
JA  - Pediatr. Blood Cancer
VL  - 50
IS  - 3
SN  - 1545-5009
UR  - https://doi.org/10.1002/pbc.21102
DO  - doi:10.1002/pbc.21102
SP  - 687
EP  - 689
KW  - hypocalcemia
KW  - multifocal osteosarcoma
KW  - secondary hyperparathyroidism
PY  - 2008
AB  - Abstract We report the case of a 16-year-old male with multifocal osteosarcoma presented with symptomatic hypocalcemia. The patient presented signs of hypocalcemia accompanied by generalized bone pain and a femoral mass. Further evaluation revealed secondary hyperparathyroidism, highly elevated alkaline phosphatase levels, and generalized sclerotic and lytic lesions. Biopsy confirmed osteosarcomatosis. Despite aggressive chemotherapy, he died from progressive disease 2 months after diagnosis. The course of disease in this patient suggests that hypocalcemia reflects a poor prognosis. Pediatr Blood Cancer 2008;50:687?689. ? 2007 Wiley-Liss, Inc.
ER  - 

AU  - Nguyen, Thach N.
AU  - Gibson, C. Michael
AU  - Petrovski, Borce
AU  - Makam, Prakash
AU  - Cong, Nguyen Duc
AU  - Khai, Pham Gia
C7  - pp. 19-49
TI  - ST-Elevation Acute Myocardial Infarction
SN  - 9781405140317
UR  - https://doi.org/10.1002/9780470750858.ch2
DO  - doi:10.1002/9780470750858.ch2
SP  - 19-49
KW  - thrombolytic therapy
KW  - comprehensive management
KW  - coronary intervention
KW  - acetylsalicyic acid
KW  - thienopyridine
PY  - 2008
AB  - Summary This chapter contains sections titled: Introduction Thrombolytic Therapy Primary Coronary Intervention Acetylsalicyic Acid Thienopyridine Glycoprotein 2B3A Inhibitors Unfractionated Heparin Low Molecular Weight Heparin Direct Thrombin Inhibitor Factor X Inhibitor ?-Blockers Angiotensin Converting Enzyme Inhibitors Angiotensin II Receptor Blockers Lipid Lowering Drugs Comprehensive Management Difficult Situations and Suggested Solutions
ER  - 

TY  - JOUR
TI  - Oral Sessions
JO  - American Journal of Transplantation
JA  - American Journal of Transplantation
VL  - 13
IS  - S5
SN  - 9781405140317
UR  - https://doi.org/10.1111/ajt.12265
DO  - doi:10.1111/ajt.12265
SP  - 29
EP  - 206
PY  - 2013
AB  - First page of article
ER  - 

TY  - JOUR
TI  - Paper Abstract
JO  - Journal of the American Geriatrics Society
JA  - J Am Geriatr Soc
VL  - 67
IS  - S1
SN  - 9781405140317
UR  - https://doi.org/10.1111/jgs.15898
DO  - doi:10.1111/jgs.15898
SP  - S1
EP  - S384
PY  - 2019
ER  - 

TY  - JOUR
TI  - 2013 ACVIM Forum Research Abstracts Program
JO  - Journal of Veterinary Internal Medicine
JA  - J Vet Intern Med
VL  - 27
IS  - 3
SN  - 9781405140317
UR  - https://doi.org/10.1111/jvim.12100
DO  - doi:10.1111/jvim.12100
SP  - 604
EP  - 756
PY  - 2013
ER  - 

TY  - JOUR
TI  - ACRT-SCTS Scholar Abstracts
JO  - Clinical and Translational Science
VL  - 3
IS  - 2
SN  - 9781405140317
UR  - https://doi.org/10.1111/j.1752-8062.2010.00181_2.x
DO  - doi:10.1111/j.1752-8062.2010.00181_2.x
SP  - S8
EP  - S55
PY  - 2010
ER  - 

TY  - JOUR
AU  - Previsdomini, Marco
AU  - Graziano, Elisa
AU  - Decosterd, Laurent
AU  - Courlet, Perrine
AU  - Perren, Andreas
AU  - Ceschi, Alessandro
C8  - LET-00101-19.R1
TI  - Severe rosuvastatin accumulation with rhabdomyolysis due to drug interactions and low cardiac output syndrome
JO  - British Journal of Clinical Pharmacology
JA  - Br J Clin Pharmacol
VL  - 85
IS  - 7
SN  - 9781405140317
UR  - https://doi.org/10.1111/bcp.13950
DO  - doi:10.1111/bcp.13950
SP  - 1616
EP  - 1618
PY  - 2019
ER  - 

TY  - JOUR
AU  - Klein, Lloyd W.
AU  - Sheldon, Mark W.
AU  - Brinker, Jeffrey
AU  - Mixon, Timothy A.
AU  - Skelding, Kimberly
AU  - Strunk, Adam O.
AU  - Tommaso, Carl L.
AU  - Weiner, Bonnie
AU  - Bailey, Steven R.
AU  - Uretsky, Barry
AU  - Kern, Morton
AU  - Laskey, Warren
TI  - The use of radiographic contrast media during PCI: A focused review
JO  - Catheterization and Cardiovascular Interventions
JA  - Cathet. Cardiovasc. Intervent.
VL  - 74
IS  - 5
SN  - 9781405140317
UR  - https://doi.org/10.1002/ccd.22113
DO  - doi:10.1002/ccd.22113
SP  - 728
EP  - 746
PY  - 2009
ER  - 

TY  - JOUR
TI  - Oral Sessions
JO  - Transplant International
VL  - 24
IS  - s2
SN  - 9781405140317
UR  - https://doi.org/10.1111/j.1432-2277.2011.01346.x
DO  - doi:10.1111/j.1432-2277.2011.01346.x
SP  - 1
EP  - 95
PY  - 2011
ER  - 

TY  - JOUR
TI  - Oral Abstracts
JO  - American Journal of Transplantation
JA  - Am J Transplant
VL  - 19
IS  - S3
SN  - 9781405140317
UR  - https://doi.org/10.1111/ajt.15405
DO  - doi:10.1111/ajt.15405
SP  - 310
EP  - 590
PY  - 2019
ER  - 

TY  - JOUR
TI  - The ILTS 18th Annual International Congress
JO  - Liver Transplantation
JA  - Liver Transpl
VL  - 18
IS  - S1
SN  - 9781405140317
UR  - https://doi.org/10.1002/lt.23435
DO  - doi:10.1002/lt.23435
SP  - S1
EP  - S306
PY  - 2012
ER  - 

TY  - JOUR
TI  - Abstracts and Index of Authors
JO  - Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
VL  - 25
IS  - 10
SN  - 9781405140317
UR  - https://doi.org/10.1592/phco.2005.25.10.1431
DO  - doi:10.1592/phco.2005.25.10.1431
SP  - 1431
EP  - 1551
PY  - 2005
ER  - 

TY  - JOUR
TI  - Abstract Presentations from the AABB Annual Meeting Orlando, FL, October 22–25, 2016
JO  - Transfusion
JA  - Transfusion
VL  - 56
IS  - S4
SN  - 9781405140317
UR  - https://doi.org/10.1111/trf.13807
DO  - doi:10.1111/trf.13807
SP  - 3A
EP  - 262A
PY  - 2016
ER  - 
